All Stories

  1. Latency of tobacco smoking for head and neck cancer among HPV‐positive and HPV‐negative individuals
  2. Vaccination of Young Women Decreases Human Papillomavirus Transmission in Heterosexual Couples: Findings from the HITCH Cohort Study
  3. Predictive Value of HPV Testing in Self-collected and Clinician-Collected Samples Compared with Cytology in Detecting High-grade Cervical Lesions
  4. Improving the reporting of cancer-specific mortality and survival in research using cancer registry data
  5. Lack of association between human papillomavirus types 6 and 11 genetic variants and cervical abnormalities: The Ludwig-McGill cohort study
  6. Efficacy of a Carrageenan gel Against Transmission of Cervical HPV (CATCH): interim analysis of a randomized, double-blind, placebo-controlled, phase 2B trial
  7. Human Papillomavirus Infection and Transmission Among Couples Through Heterosexual Activity (HITCH) Cohort Study: Protocol Describing Design, Methods, and Research Goals
  8. Evidence for cross-protection but not type-replacement over the 11 years after human papillomavirus vaccine introduction
  9. Increased risk of oropharyngeal cancers mediated by oral human papillomavirus infection: Results from a Canadian study
  10. Prevention of cervical cancer in Latin America: Future challenges and opportunities
  11. Use of HPV testing in cervical cancer screening services in Mexico, 2008-2018: a nationwide database study
  12. Age at last screening and remaining lifetime risk of cervical cancer in older, unvaccinated women: a modelling study
  13. Assessing the Time Dependence of Prognostic Values of Cytology and Human Papillomavirus Testing in Cervical Cancer Screening
  14. Comparative performance of human papillomavirus messenger RNA versus DNA screening tests at baseline and 48 months in the HPV FOCAL trial
  15. Effect of Screening With Primary Cervical HPV Testing vs Cytology Testing on High-grade Cervical Intraepithelial Neoplasia at 48 Months
  16. Restoring Dignity in Academic Publishing Is a Collective Duty
  17. HLA and KIR Associations of Cervical Neoplasia
  18. Validation of a New HPV Self-Sampling Device for Cervical Cancer Screening
  19. Effect of Screening With Primary Cervical HPV Testing vs Cytology Testing on High-grade Cervical Intraepithelial Neoplasia at 48 Months
  20. Epidemiology of Any and Vaccine-Type Anogenital Human Papillomavirus Among 13–26-Year-Old Young Men After HPV Vaccine Introduction
  21. Estimating the current and future cancer burden in Canada: methodological framework of the Canadian population attributable risk of cancer (ComPARe) study
  22. Human Papillomavirus Infection and Transmission Among Couples Through Heterosexual Activity (HITCH) Cohort Study: Protocol Describing Design, Methods, and Research Goals (Preprint)
  23. Human papillomavirus vaccination and the role of herd effects in future cancer control planning: a review
  24. Journal editors as curators of scholarship: A case study in repairing the scientific record
  25. Who's Not Protected in the Herd? Factors Associated with Vaccine-Type HPV in Unvaccinated Women
  26. Validation of a new HPV self-sampling device for cervical cancer screening: The Cervical and Self-Sample In Screening (CASSIS) study
  27. Self-sampling for cervical cancer screening: Empowering women to lead a paradigm change in cancer control
  28. Persistence of human papillomavirus 16, 18 and 52 variants in Inuit women from Northern Quebec, Canada
  29. The performance of mobile screening units in a breast cancer screening program in Brazil
  30. Human Papillomavirus Vaccination: Making Sense of the Public Controversy
  31. Mobile Screening Units for the Early Detection of Cancer: A Systematic Review
  32. Non-Vaccine-Type HPV Prevalence after Vaccine Introduction
  33. Aetiological heterogeneity of head and neck squamous cell carcinomas: the role of human papillomavirus infections, smoking and alcohol
  34. Estimating HPV DNA Deposition Between Sexual Partners Using HPV Concordance, Y Chromosome DNA Detection, and Self-reported Sexual Behaviors
  35. Argon plasma coagulation treatment of anal high-grade squamous intraepithelial lesions in men who have sex with men living with HIV: results of a 2-year prospective pilot study
  36. Defining the genetic susceptibility to cervical neoplasia—A genome-wide association study
  37. Y Chromosome DNA in Womenʼs Vaginal Samples as a Biomarker of Recent Vaginal Sex and Condom Use With Male Partners in the HPV Infection and Transmission Among Couples Through Heterosexual Activity Cohort Study
  38. Optimizing secondary prevention of cervical cancer: Recent advances and future challenges
  39. Population health intervention research: A renewed commitment to promoting a science of solutions
  40. The Downside of the Shifting Paradigm of Scholarly Publishing in the Biomedical Sciences: Predatory Publishing
  41. L’inconvénient du changement de paradigme dans l’édition savante en sciences biomédicales : l’arrivée des éditeurs prédateurs
  42. Assortativity and Mixing by Sexual Behaviors and Sociodemographic Characteristics in Young Adult Heterosexual Dating Partnerships
  43. Human papillomavirus genotypes and risk of head and neck cancers: Results from the HeNCe Life case-control study
  44. Approaches for triaging women who test positive for human papillomavirus in cervical cancer screening
  45. Independent Scientists Provide Guidance for the Future of Cervical Cancer Screening
  46. Introduction of molecular HPV testing as the primary technology in cervical cancer screening: Acting on evidence to change the current paradigm
  47. Cervical Infection with Cutaneous Beta and Mucosal Alpha Papillomaviruses
  48. Ottawa Statement from the Sparking Solutions Summit on Population Health Intervention Research
  49. Aptima HPV Assay versus Hybrid Capture® 2 HPV test for primary cervical cancer screening in the HPV FOCAL trial
  50. Determinants of Cervical Cancer Screening Accuracy for Visual Inspection with Acetic Acid (VIA) and Lugol’s Iodine (VILI) Performed by Nurse and Physician
  51. Comparison of Triage Strategies for HPV-Positive Women: Canadian Cervical Cancer Screening Trial Results
  52. Does hormonal therapy for fertility preservation affect the survival of young women with early-stage endometrial cancer?
  53. Epidemiologic Evaluation of Human Papillomavirus Type Competition and the Potential for Type Replacement Post-Vaccination
  54. Disease detection and resource use in the safety and control arms of the HPV FOCAL cervical cancer screening trial
  55. Distribution of Vaccine-Type Human Papillomavirus Does Not Differ by Race or Ethnicity Among Unvaccinated Young Women
  56. HPV for cervical cancer screening (HPV FOCAL): Complete Round 1 results of a randomized trial comparing HPV-based primary screening to liquid-based cytology for cervical cancer
  57. Substantial Decline in Vaccine-Type Human Papillomavirus (HPV) Among Vaccinated Young Women During the First 8 Years After HPV Vaccine Introduction in a Community
  58. Nonlinear association between betel quid chewing and oral cancer: Implications for prevention
  59. Population-based prevalence of cervical infection with human papillomavirus genotypes 16 and 18 and other high risk types in Tlaxcala, Mexico
  60. Human papillomavirus testing versus cytology in primary cervical cancer screening: End-of-study and extended follow-up results from the Canadian cervical cancer screening trial
  61. Should we lower the age for routine HPV vaccination in the United States?
  62. Recommendations for Implementing Human Papillomavirus-Based Cervical Cancer Screening: Lessons Learned from the HPV FOCAL Trial
  63. Incidence and duration of type-specific human papillomavirus infection in high-risk HPV-naïve women: results from the control arm of a phase II HPV-16/18 vaccine trial
  64. A collaboration between cousins: The Canadian Journal of Public Health and the Canadian Society for Epidemiology and Biostatistics
  65. Periodontal diseases and risk of oral cancer in Southern India: Results from the HeNCe Life study
  66. Cervical Infection With Vaccine-Associated Human Papillomavirus (HPV) Genotypes as a Predictor of Acquisition and Clearance of Other HPV Infections
  67. Reproductive and genital health and risk of cervical human papillomavirus infection: results from the Ludwig-McGill cohort study
  68. Correlates of women’s intentions to be screened for human papillomavirus for cervical cancer screening with an extended interval
  69. Cervical cancer screening of HPV vaccinated populations: Cytology, molecular testing, both or none
  70. Triage strategies in cervical cancer detection in Mexico: methods of the FRIDA Study
  71. Assessment of mediators of racial disparities in cervical cancer survival in the United States
  72. World Health Organization Guidelines for treatment of cervical intraepithelial neoplasia 2-3 and screen-and-treat strategies to prevent cervical cancer
  73. Human papillomavirus variants among Inuit women in northern Quebec, Canada
  74. Comparison of the Roche cobas® 4800 and Digene Hybrid Capture® 2 HPV tests for primary cervical cancer screening in the HPV FOCAL trial
  75. Assortative mixing as a source of bias in epidemiological studies of sexually transmitted infections: the case of smoking and human papillomavirus
  76. Risk of Human Papillomavirus (HPV) Infection and Cervical Neoplasia after Pregnancy
  77. What makes an eLife paper in epidemiology and global health?
  78. An elusive low-hanging fruit for public health: Gun violence prevention
  79. No role for human papillomavirus infection in oral cancers in a region in southern India
  80. HPV DNA testing with cytology triage in cervical cancer screening: Influence of revealing HPV infection status
  81. Sobering realizations in cancer prevention and screening and their lessons
  82. Incidence, Persistence, and Determinants of Human Papillomavirus Infection in a Population of Inuit Women in Northern Quebec
  83. Projected Impact of HPV and LBC Primary Testing on Rates of Referral for Colposcopy in a Canadian Cervical Cancer Screening Program
  84. Prevalence of high-risk human papilloma virus genotypes and associated risk of cervical precancerous lesions in a large U.S. screening population: Data from the ATHENA trial
  85. Perfect is the Enemy of Good: Going to the War on Cancer with Less Evidence than We Could Have
  86. Urologist referral delay and its impact on survival after radical cystectomy for bladder cancer
  87. Determinants of baseline seroreactivity to human papillomavirus type 16 in the Ludwig-McGill cohort study
  88. Sexual Transmission of Oral Human Papillomavirus Infection among Men
  89. Women’s intentions to self-collect samples for human papillomavirus testing in an organized cervical cancer screening program
  90. Evaluation of Human Papillomavirus Type Replacement Postvaccination Must Account for Diagnostic Artifacts: Masking of HPV52 by HPV16 in Anogenital Specimens
  91. Comparing the cost-effectiveness of two- and three-dose schedules of human papillomavirus vaccination: A transmission-dynamic modelling study
  92. Epidemiology of cervical cancer
  93. Screening for cervical cancer
  94. Striving for excellence while adapting to change: Redefining our mission of serving the preventive medicine community
  95. Human papillomavirus vaccines: key factors in planning cost-effective vaccination programs
  96. Methylation of viral and host genes and severity of cervical lesions associated with human papillomavirus type 16
  97. Screening histories and contact with physicians as determinants of cervical cancer risk in Montreal, Quebec
  98. Predictors of preoperative delays before radical cystectomy for bladder cancer in Quebec, Canada: a population‐based study
  99. HPV testing with cytology triage for cervical cancer screening in routine practice
  100. Global Genomic Diversity of Human Papillomavirus 6 Based on 724 Isolates and 190 Complete Genome Sequences
  101. Determinants of Prevalent Human Papillomavirus in Recently Formed Heterosexual Partnerships: A Dyadic-Level Analysis
  102. Determinants of Human Papillomavirus Coinfections among Montreal University Students: The Influence of Behavioral and Biologic Factors
  103. Making Prospective Registration of Observational Research a Reality
  104. Embracing a new era in cervical cancer screening
  105. The road ahead for cervical cancer prevention and control
  106. Is there a need for a new journal devoted to preventive medicine?
  107. cobas®4800 HPV Test, a real-time polymerase chain reaction assay for the detection of human papillomavirus in cervical specimens
  108. Comprehensive Control of Human Papillomavirus Infections and Related Diseases
  109. Comprehensive Control of Human Papillomavirus Infections and Related Diseases
  110. Comprehensive Control of Human Papillomavirus Infections and Related Diseases
  111. The association between human leukocyte antigen (HLA)-G polymorphisms and human papillomavirus (HPV) infection in Inuit women of northern Quebec
  112. Human papillomavirus type 56 polymorphism in Canadian women with and without cervical lesions
  113. Comprehensive Control of Human Papillomavirus Infections and Related Diseases
  114. Potential cost-effectiveness of the nonavalent human papillomavirus (HPV) vaccine
  115. Lung Cancer Screening: Review and Performance Comparison Under Different Risk Scenarios
  116. Polymorphisms in Genes Involved in Folate Metabolism Modify the Association of Dietary and Circulating Folate and Vitamin B-6 with Cervical Neoplasia
  117. Combatting obesity — A helping hand from the business community
  118. Counterpoint: Cervical Cancer Screening Guidelines--Approaching the Golden Age
  119. The frequency of HLA alleles in a population of Inuit women of northern Quebec
  120. Comparative cost-effectiveness of the quadrivalent and bivalent human papillomavirus vaccines: A transmission-dynamic modeling study
  121. Women's intentions to receive cervical cancer screening with primary human papillomavirus testing
  122. Vaccinating Girls and Boys with Different Human Papillomavirus Vaccines: Can It Optimise Population-Level Effectiveness?
  123. Polymorphism in the promoter region of the Toll-like receptor 9 gene and cervical human papillomavirus infection
  124. Human papillomavirus type 16 viral load measurement as a predictor of infection clearance
  125. Epidemiologic Approaches to Evaluating the Potential for Human Papillomavirus Type Replacement Postvaccination
  126. Factors associated with cervical cancer screening uptake among Inuit women in Nunavik, Quebec, Canada
  127. Influence of Postoperative Infectious Complications on Long-Term Survival of Lung Cancer Patients: A Population-Based Cohort Study
  128. 77 PREOPERATIVE DELAYS PRIOR TO RADICAL CYSTECTOMY IN PATIENTS WITH BLADDER CANCER: A POPULATION-BASED STUDY
  129. Response
  130. Assessment of the performance of algorithms for cervical cancer screening: Evidence from the Ludwig–McGill cohort study
  131. Accuracy of p53 Codon 72 Polymorphism Status Determined by Multiple Laboratory Methods: A Latent Class Model Analysis
  132. Carrageenan Against Transmission of Cervical Human papillomavirus (HPV)
  133. Vaccination and Screening in Cervical Cancer Control and Prevention
  134. Preventive Medicine: New Editorial Office but the Same Vision
  135. The Canadian Cervical Cancer Screening Trial of human papillomavirus (HPV) testing versus Pap cytology
  136. Towards more eclectic evidence-based medicine in cancer prevention and control
  137. Human papillomavirus type 52 polymorphism and high-grade lesions of the uterine cervix
  138. Primary cervical cancer screening with HPV testing compared with liquid-based cytology: results of round 1 of a randomised controlled trial – the HPV FOCAL Study
  139. Human Papillomavirus and Cancer Prevention: Gaps in Knowledge and Prospects for Research, Policy, and Advocacy
  140. Cervical human papillomavirus detection is not affected by menstrual phase
  141. Population-Level Impact of the Bivalent, Quadrivalent, and Nonavalent Human Papillomavirus Vaccines: A Model-Based Analysis
  142. Patterns of persistent genital human papillomavirus infection among women worldwide: A literature review and meta-analysis
  143. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis
  144. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology Screening Guidelines for the Prevention and Early Detection of Cervical Cancer
  145. Performance of an Adipokine Pathway-Based Multilocus Genetic Risk Score for Prostate Cancer Risk Prediction
  146. Outcomes and Cost Comparisons After Introducing a Robotics Program for Endometrial Cancer Surgery
  147. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology Screening Guidelines for the Prevention and Early Detection of Cervical Cancer
  148. Inuit women's attitudes and experiences towards cervical cancer and prevention strategies in Nunavik, Quebec
  149. Circulating Biomarkers of Iron Storage and Clearance of Incident Human Papillomavirus Infection
  150. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer
  151. Burden of disease, health indicators and challenges for epidemiology in North America
  152. Dry self-sampling versus provider-sampling of cervicovaginal specimens for human papillomavirus detection in the Inuit population of Nunavik, Quebec
  153. Human Papillomavirus (HPV) DNA Triage of Women with Atypical Squamous Cells of Undetermined Significance with cobas 4800 HPV and Hybrid Capture 2 Tests for Detection of High-Grade Lesions of the Uterine Cervix
  154. Comparison of human papillomavirus testing and cytology for cervical cancer screening in a primary health care setting in the Democratic Republic of the Congo
  155. Human leukocyte antigen G polymorphism is associated with an increased risk of invasive cancer of the uterine cervix
  156. Epidemiology, natural history and risk factors for anal intraepithelial neoplasia
  157. Ano-genital human papillomavirus type 97 infection is detected in Canadian men but not women at risk or infected with the human immunodeficiency virus
  158. Biomarkers of oxidant load and type-specific clearance of prevalent oncogenic human papillomavirus infection: Markers of immune response?
  159. Genital Transmission of Human Papillomavirus in Recently Formed Heterosexual Couples
  160. Epidemiology and burden of HPV infection and related diseases: Implications for prevention strategies
  161. The Impact of Anogenital Warts on Health-Related Quality of Life: A 6-Month Prospective Study
  162. Human Papillomavirus Vaccines
  163. Human papillomavirus vaccines
  164. Generic Microtiter Plate Assay for Triaging Clinical Specimens Prior to Genotyping of Human Papillomavirus DNA via Consensus PCR
  165. Incremental Impact of Adding Boys to Current Human Papillomavirus Vaccination Programs: Role of Herd Immunity
  166. The psychosocial impact of an abnormal cervical smear result
  167. Optimizing technology for cervical cancer screening in high-resource settings
  168. Distribution of human papillomavirus genotypes in cervical intraepithelial neoplasia and invasive cervical cancer in Canada
  169. Human leukocyte antigen (HLA)-E and HLA-G polymorphisms in human papillomavirus infection susceptibility and persistence
  170. HAART and Progression to High-Grade Anal Intraepithelial Neoplasia in Men Who Have Sex with Men and Are Infected with HIV
  171. Loss of quality of life associated with genital warts: baseline analyses from a prospective study
  172. Use of Non-Steroidal Anti-Inflammatory Drugs and Prostate Cancer Risk: A Population-Based Nested Case-Control Study
  173. Prevalence and Determinants of High-Risk Human Papillomavirus Infection in Women From a Sub-Saharan African Community
  174. Associations of dietary dark-green and deep-yellow vegetables and fruits with cervical intraepithelial neoplasia: modification by smoking
  175. Human Papillomavirus (HPV) DNA Triage of Women with Atypical Squamous Cells of Undetermined Significance with Amplicor HPV and Hybrid Capture 2 Assays for Detection of High-Grade Lesions of the Uterine Cervix
  176. Economic evaluation of strategies for managing women with equivocal cytological results in Brazil
  177. Human papillomavirus (HPV) types 16, 18, 31, 45 DNA loads and HPV-16 integration in persistent and transient infections in young women
  178. Integrating novel primary- and secondary-prevention strategies: the next challenge for cervical cancer control
  179. Human Papillomavirus Infection and Reinfection in Adult Women: the Role of Sexual Activity and Natural Immunity
  180. Persistent HPV Infection and Cervical Cancer Risk: Is the Scientific Rationale for Changing the Screening Paradigm Enough?
  181. Radiodiagnostic Imaging in Pregnancy and the Risk of Childhood Malignancy: Raising the Bar
  182. Dietary consumption of antioxidant nutrients and risk of incident cervical intraepithelial neoplasia
  183. Are endometrial polyps true cancer precursors?
  184. Episomal and integrated human papillomavirus type 16 loads and anal intraepithelial neoplasia in HIV-seropositive men
  185. No Association between Endogenous Retinoic Acid and Human Papillomavirus Clearance or Incident Cervical Lesions in Brazilian Women
  186. Polymorphism of the capsid L1 gene of human papillomavirus types 31, 33, and 35
  187. The impact of intolerance of uncertainty on anxiety after receiving an informational intervention about HPV: A randomised controlled study
  188. Awareness and Knowledge about Human Papillomavirus Among Inuit Women in Nunavik, Quebec
  189. What is the role of HPV typing in the United States now and in the next five years in a vaccinated population?
  190. Determinants of Human Papillomavirus Infection Among Inuit Women of Northern Quebec, Canada
  191. A randomized controlled trial of Human Papillomavirus (HPV) testing for cervicalcancer screening: trial design and preliminary results (HPV FOCAL Trial)
  192. Diet and serum micronutrients in relation to cervical neoplasia and cancer among low-income Brazilian women
  193. Use of nonsteroidal anti-inflammatory drugs and prostate cancer risk: A meta-analysis
  194. Use of the Normalized Absorbance Ratio as an Internal Standardization Approach To Minimize Measurement Error in Enzyme-Linked Immunosorbent Assays for Diagnosis of Human Papillomavirus Infection
  195. Human Papillomavirus Infections Among Couples in New Sexual Relationships
  196. Influence of Partnerʼs Infection Status on Prevalent Human Papillomavirus Among Persons With a New Sex Partner
  197. Promising strategies for cervical cancer screening in the post-human papillomavirus vaccination era
  198. Validation of dot blot hybridization and denaturing high performance liquid chromatography as reliable methods for TP53 codon 72 genotyping in molecular epidemiologic studies
  199. Invited Commentary: Human Papillomavirus Infection and Risk of Cervical Precancer--Using the Right Methods to Answer the Right Questions
  200. Human papillomavirus testing with Pap triage for cervical cancer prevention in Canada: a cost-effectiveness analysis
  201. A New Generation of Studies of Human Papillomavirus DNA Testing in Cervical Cancer Screening
  202. Effectiveness of Cervical Cancer Screening at Different Ages
  203. Determinants of delays in treatment initiation in children and adolescents diagnosed with leukemia or lymphoma in Canada
  204. Brief Research Report: Uncertainty-Inducing and Reassuring Facts About HPV: A Descriptive Study of French Canadian Women
  205. Epidemiologyʼs Contributions to a Nobel Prize Recognition
  206. The Expected Impact of HPV Vaccination on the Accuracy of Cervical Cancer Screening: The Need for a Paradigm Change
  207. Managing low grade and borderline cervical abnormalities
  208. Is the UK ready to embrace HPV testing?
  209. Low-risk human papillomavirus type 6 DNA load and integration in cervical samples from women with squamous intraepithelial lesions
  210. Prevalence, Clearance, and Incidence of Anal Human Papillomavirus Infection in HIV‐Infected Men: The HIPVIRG Cohort Study
  211. Persistence of an Incident Human Papillomavirus Infection and Timing of Cervical Lesions in Previously Unexposed Young Women
  212. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older
  213. Prognostic Value of Measuring Load of Human Papillomavirus DNA in Cervical Samples: An Elusive Target
  214. Bernard Duval: The Architect of Quebec’s HPV Immunization Programme
  215. How Multidisciplinary Research Advanced the Mission of Cervical Cancer Prevention
  216. Infectious Diseases and Cancer: HPV
  217. Integrating Human Papillomavirus Vaccination in Cervical Cancer Control Programmes
  218. Detection and Typing of Human Papillomavirus Nucleic Acids in Biological Fluids
  219. Prevalence and Age Distribution of Human Papillomavirus Infection in a Population of Inuit Women in Nunavik, Quebec
  220. Delays in diagnosis and treatment among children and adolescents with cancer in Canada
  221. Optimization of primary and secondary cervical cancer prevention strategies in an era of cervical cancer vaccination: A multi-regional health economic analysis
  222. Cost-effectiveness analysis: An essential tool to inform public health policy in cervical cancer prevention
  223. Genotyping of Human Papillomavirus DNA in Anal Biopsies and Anal Swabs Collected From HIV-Seropositive Men With Anal Dysplasia
  224. Interaction between polymorphisms of the Human Leukocyte Antigen and HPV-16 Variants on the risk of invasive cervical cancer
  225. Use of latent class models to accommodate inter-laboratory variation in assessing genetic polymorphisms associated with disease risk
  226. Integration of Human Papillomavirus Vaccination and Cervical Cancer Screening in Latin America and the Caribbean
  227. Recommendations for Cervical Cancer Prevention in Latin America and the Caribbean
  228. Influence of human papillomavirus type 16 (HPV-16) E2 polymorphism on quantification of HPV-16 episomal and integrated DNA in cervicovaginal lavages from women with cervical intraepithelial neoplasia
  229. Type‐Specific Duration of Human Papillomavirus Infection: Implications for Human Papillomavirus Screening and Vaccination
  230. Human papillomavirus vaccination and screening as the new paradigm in cervical cancer prevention
  231. Commentary: Smoking and human papillomavirus infection: the pursuit of credibility for an epidemiologic association
  232. Cervical cancer screening following prophylactic human papillomavirus vaccination
  233. Reassessing the Epidemiology of Human Papillomavirus Infection: Back to Basics
  234. Human papillomavirus infection and oral cancer: A case-control study in Montreal, Canada
  235. Ovarian cancer and oral contraceptives
  236. Selected class I and class II HLA alleles and haplotypes and risk of high-grade cervical intraepithelial neoplasia
  237. Vaccination against human papillomavirus
  238. Response to Pretorius and Belinson
  239. BROGLY ET AL. RESPOND
  240. Newly-isolated HPV97, related to HPV18 and 45 is frequently detected in HIV-positive men from the montreal area
  241. Human Papillomavirus DNA versus Papanicolaou Screening Tests for Cervical Cancer
  242. Haptoglobin phenotype and risk of cervical neoplasia: A case-control study
  243. Confirmatory Real-Time PCR Assay for Human Papillomavirus (HPV) Type 52 Infection in Anogenital Specimens Screened for HPV Infection with the Linear Array HPV Genotyping Test
  244. THE AUTHORS REPLY
  245. Cost-effectiveness of HPV 16, 18 vaccination in Brazil
  246. Prophylactic human papillomavirus vaccines: potential for sea change
  247. Process of care failures in invasive cervical cancer: Systematic review and meta-analysis
  248. HLA Polymorphisms and Cervical Human Papillomavirus Infection in a Cohort of Montreal University Students
  249. Multiparameter Calibration of a Natural History Model of Cervical Cancer
  250. Cervical cancer screening following the implementation of prophylactic human papillomavirus vaccination
  251. Reproductive Health of Adolescent Girls Perinatally Infected With HIV
  252. A New Window into the Natural History of Human Papillomavirus Infection: A View from the ALTS (Atypical Squamous Cells of Undetermined Significance/Low‐Grade Squamous Intraepithelial Lesions Triage Study) Trial
  253. Are self-collected samples comparable to physician-collected cervical specimens for human papillomavirus DNA testing? A systematic review and meta-analysis
  254. Re: Human Papillomavirus Type 16 and 18 Variants: Race-Related Distribution and Persistence
  255. Epidemiological methods: a view from the Americas
  256. Insulin-like Growth Factor-I and Risk of High-Grade Cervical Intraepithelial Neoplasia
  257. High grade cervical lesions are caused preferentially by non-European variants of HPVs 16 and 18
  258. Diagnosis delays in childhood cancer
  259. Koilocytosis in Oral Squamous Cell Carcinoma: What Does It Mean?
  260. Viral load of episomal and integrated forms of human papillomavirus type 33 in high-grade squamous intraepithelial lesions of the uterine cervix
  261. Polymorphism of the L1 Capsid Gene and Persistence of Human Papillomavirus Type 52 Infection in Women at High Risk or Infected by HIV
  262. Estimating the long-term impact of a prophylactic human papillomavirus 16/18 vaccine on the burden of cervical cancer in the UK
  263. Human Papillomavirus Infections With Multiple Types and Risk of Cervical Neoplasia
  264. Cancer Precursors
  265. Lack of Agreement Between Cervicography and Cytology and the Effect of Human Papillomavirus Infection and Viral Load
  266. Human Papillomavirus Type 33 Polymorphisms and High‐Grade Squamous Intraepithelial Lesions of the Uterine Cervix
  267. Chapter 20: Issues in planning cervical cancer screening in the era of HPV vaccination
  268. Chapter 30: HPV vaccines and screening in the prevention of cervical cancer; conclusions from a 2006 workshop of international experts
  269. Chapter 6: Epidemiology and transmission dynamics of genital HPV infection
  270. Chapter 29: Knowledge gaps and priorities for research on prevention of HPV infection and cervical cancer
  271. Randomized controlled trial of human papillomavirus testing versus Pap cytology in the primary screening for cervical cancer precursors: Design, methods and preliminary accrual results of the Canadian cervical cancer screening trial (CCCaST)
  272. Is HPV testing with cytological triage a more logical approach in cervical cancer screening?
  273. Human Papillomavirus Infections with Multiple Types and Risk of Cervical Neoplasia
  274. Enhanced Detection and Typing of Human Papillomavirus (HPV) DNA in Anogenital Samples with PGMY Primers and the Linear Array HPV Genotyping Test
  275. Diversity of cutaneous human papillomavirus types in individuals with and without skin lesion
  276. Non-steroidal anti-inflammatory drug use and prostate cancer in a high-risk population
  277. Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial
  278. Managing low-grade cervical lesions
  279. The epidemiology of genital human papillomavirus infection
  280. Human papillomavirus testing improves the accuracy of colposcopy in detection of cervical intraepithelial neoplasia
  281. Advances in Prevention of Cervical Cancer and Other Human Papillomavirus-Related Diseases
  282. Modeling the Sexual Transmissibility of Human Papillomavirus Infection using Stochastic Computer Simulation and Empirical Data from a Cohort Study of Young Women in Montreal, Canada
  283. Epidemiology As a Tool to Reveal Inequalities in Breast Cancer Care
  284. Epidemiology of Oncogenic and Nononcogenic HPV Types, and the Evidence for Differences in Their Sexual Transmissibility
  285. Associations between serum carotenoids and tocopherols and type-specific HPV persistence: The Ludwig-McGill cohort study
  286. Visual inspection as a cervical cancer screening method in a primary health care setting in Africa
  287. High-risk human papillomavirus infection of the genital tract of women with a previous history or current high-grade vulvar intraepithelial neoplasia
  288. Comparison of Psychosocial Outcomes in Head and Neck Cancer Patients Receiving a Coping Strategies Intervention and Control Subjects Receiving No Intervention
  289. Management of low-grade cervical lesions in young women
  290. Efficacy of a Bivalent L1 Virus-Like Particle Vaccine in Prevention of Infection With Human Papillomavirus Types 16 and 18 in Young Women: A Randomized, Controlled Trial
  291. Modifiable Risk Factors Associated with Clearance of Type-Specific Cervical Human Papillomavirus Infections in a Cohort of University Students
  292. Vaccination against human papillomavirus infection: a new paradigm in cervical cancer control
  293. Different P105 Promoter Activities among Natural Variants of Human Papillomavirus Type 18
  294. Efficacy of a Bivalent L1 Virus-Like Particle Vaccine in Prevention of Infection With Human Papillomavirus Types 16 and 18 in Young Women: A Randomized Trial
  295. The Role of Human Papillomaviruses in Cancer
  296. The p53 codon 72 polymorphism and risk of high-grade cervical intraepithelial neoplasia
  297. The Laboratory Diagnosis of Genital Human Papillomavirus Infections
  298. Role and limitations of epidemiology in establishing a causal association
  299. Screening every three years, instead of annually, would result in a small increase in risk of cervical cancer
  300. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial
  301. Rapport du Forum Pancanadien sur la Prévention et la Maîtrise du Cancer du col Utérin de 2003
  302. Report of the 2003 Pan-Canadian Forum on Cervical Cancer Prevention and Control
  303. Polio vaccines, Simian Virus 40, and human cancer: the epidemiologic evidence for a causal association
  304. Silver leaf nylon dressing to prevent radiation dermatitis in patients undergoing chemotherapy and external beam radiotherapy to the perineum
  305. Intensity of drug injection as a determinant of sustained injection cessation among chronic drug users: the interface with social factors and service utilization
  306. An overview of epidemiological and public health research on HPVs presented at the 21st International Papillomavirus Conference in Mexico City, 20-26 February 2004
  307. Projected Clinical Benefits and Cost-effectiveness of a Human Papillomavirus 16/18 Vaccine
  308. Male Circumcision and AIDS in Africa
  309. Human papillomavirus and cervical dysplasia in Nunavut: prelude to a screening strategy
  310. Prognostic significance of lymph node variables and human papillomavirus DNA in invasive vulvar carcinoma
  311. Evaluation of a convenient enzyme immunoassay to assess the quality of genital specimens submitted for the detection of human papillomavirus DNA by consensus PCR
  312. Cancer of the Uterine Cervix
  313. Epidemiology of Cervical, Vulvar, and Vaginal Cancers
  314. Other Gynecologic Cancers: endometrial, ovarian, vulvar and vaginal cancers
  315. Randomized controlled trials of HPV testing and pap cytology: Toward evidence-based cervical cancer prevention
  316. Prostate cancer and use of nonsteroidal anti-inflammatory drugs: systematic review and meta-analysis
  317. p53 Codon 72 Polymorphism and Cervical Neoplasia: A Meta-Analysis Review
  318. Electrofulguration for Low-Grade Squamous Intraepithelial Lesions of the Cervix (CIN 1)
  319. Are we ready for a paradigm change in cervical cancer screening?
  320. Dietary Intake and Risk of Persistent Human Papillomavirus (HPV) Infection: The Ludwig‐McGill HPV Natural History Study
  321. Modeling the Time Dependence of the Association between Human Papillomavirus Infection and Cervical Cancer Precursor Lesions
  322. Innovations in understanding the biology of cervical cancer
  323. Toward a reduction of the global burden of cervical cancer
  324. The Epidemiology of Cervical Cancer
  325. A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine
  326. Computer Programs for Epidemiologists–PEPI Version 4.0
  327. Occurrence of Cervical Infection with Multiple Human Papillomavirus Types is Associated with Age and Cytologic Abnormalities
  328. Epidemiologic correlates of antibody response to human papillomavirus among women at low risk of cervical cancer
  329. Other gynecologic cancers
  330. Cancer of the uterine cervix
  331. Prospects for controlling cervical cancer at the turn of the century
  332. Is Colposcopy Warranted in Women with External Anogenital Warts?
  333. Herpes simplex virus type II is not a cofactor to human papillomavirus in cancer of the uterine cervix
  334. Towards More Effective Public Health Programming for Injection Drug Users: Development and Evaluation of the Injection Drug User Quality of Life Scale
  335. Cervical cancer control, priorities and new directions
  336. Viral load as a predictor of the risk of cervical intraepithelial neoplasia
  337. Estrogen Replacement Therapy and Risk of Ovarian Cancer in Postmenopausal Women
  338. Estrogen Replacement Therapy and Risk of Ovarian Cancer in Postmenopausal WomenDifferences in Success Rates of Noninvasive VentilationSpirituality and Chronic IllnessPrematurity and Later Cognitive OutcomesAspiration of a Dental Appliance in a Patient ...
  339. Evidence-based policy recommendations on cancer screening and prevention
  340. Past, present, and future of HPV research: highlights from the 19th International Papillomavirus Conference-HPV2001
  341. Detection of human herpes virus type 6 DNA in precancerous lesions of the uterine cervix
  342. Persistent HPV infection is associated with a greater risk of developing cervical lesions than a single positive test
  343. Polymorphisms of the Human Leukocyte Antigen DRB1 and DQB1 Genes and the Natural History of Human Papillomavirus Infection
  344. Use of PGMY Primers in L1 Consensus PCR Improves Detection of Human Papillomavirus DNA in Genital Samples
  345. Predictive Factors for Diagnosis of Advanced-Stage Squamous Cell Carcinoma of the Head and Neck
  346. Cancer Precursors
  347. Persistent human papillomavirus infection and cervical neoplasia
  348. Assessing the gain in diagnostic performance when combining two diagnostic tests
  349. HIV-Positive Notification and Behavior Changes in Montreal Injection Drug Users
  350. Cervical Coinfection with Human Papillomavirus (HPV) Types as a Predictor of Acquisition and Persistence of HPV Infection
  351. Oncogenic Human Papillomavirus Infection and Cervical Lesions in Aboriginal Women of Nunavut, Canada
  352. Nonisotopic Detection of Human Papillomavirus DNA in Clinical Specimens Using a Consensus PCR and a Generic Probe Mix in an Enzyme-Linked Immunosorbent Assay Format
  353. Repeatability of sexual history in longitudinal studies on HPV infection and cervical neoplasia: determinants of reporting error at follow-up interviews
  354. Toward a reduction of the global burden of cervical cancer
  355. Cervical-cancer screening beyond the year 2000
  356. Analysis of Human Papillomavirus in Schneiderian Papillomas as Compared to Chronic Sinusitis and Normal Nasal Mucosa
  357. Comparison of Endocervical Curettage and Endocervical Brushing
  358. Molecular variants of human papillomavirus types 16 and 18 preferentially associated with cervical neoplasia
  359. Risk behaviour change and HIV infection among injection drug users in Montreal
  360. p53 polymorphism in codon 72 and risk of human papillomavirus‐induced cervical cancer: effect of inter‐laboratory variation
  361. The influence of parental age on the risk of Wilms' tumour
  362. Comparison of endocervical curettage and endocervical brushing
  363. Determinants of Low-Risk and High-Risk Cervical Human Papillomavirus Infections in Montreal University Students
  364. Evaluation of the potential promoting effect of 60 Hz magnetic fields on N-ethyl-N-nitrosourea induced neurogenic tumors in female F344 rats
  365. Evaluation of the potential promoting effect of 60 Hz magnetic fields onN-ethyl-N-nitrosourea induced neurogenic tumors in female F344 rats
  366. p53 polymorphism in codon 72 and risk of human papillomavirus-induced cervical cancer: effect of inter-laboratory variation
  367. Interaction between Tobacco and Alcohol Consumption and the Risk of Cancers of the Upper Aero-Digestive Tract in Brazil
  368. Epidemiology of Acquisition and Clearance of Cervical Human Papillomavirus Infection in Women from a High‐Risk Area for Cervical Cancer
  369. Design and methods of the Ludwig-McGill longitudinal study of the natural history of human papillomavirus infection and cervical neoplasia in Brazil
  370. Assessing gains in diagnostic utility when human papillomavirus testing is used as an adjunct to Papanicolaou smear in the triage of women with cervical cytologic abnormalities
  371. Effect of Smoking Cessation and Tobacco Type on the Risk of Cancers of the Upper Aero-Digestive Tract in Brazil
  372. Human papillomavirus and prognoses of patients with cancers of the upper aerodigestive tract
  373. Human papillomavirus and prognoses of patients with cancers of the upper aerodigestive tract
  374. The influence of parental age on the risk of Wilms’ tumour
  375. Epidemiologic Evidence and Human Papillomavirus Infection as a Necessary Cause of Cervical Cancer
  376. Use of wood stoves and risk of cancers of the upper aero-digestive tract: a case-control study
  377. Clinical significance of histiocytes in the detection of endometrial adenocarcinoma and hyperplasia
  378. Relationship between dental factors and risk of upper aerodigestive tract cancer
  379. Preoperative irradiation therapy and radical hysterectomy: prognostic value of tumor regression after initial irradiation of squamous cell carcinoma of the cervix
  380. The role of professional diagnostic delays in the prognosis of upper aerodigestive tract carcinoma
  381. Predictors of professional diagnostic delays for upper aerodigestive tract carcinoma
  382. Erratum
  383. Assessing Harm Reduction Strategies: The Dilemma of Observational Studies
  384. Defining Safe Drinking Water
  385. The future of HPV testing in clinical laboratories and applied virology research
  386. Human papillomavirus infection in postmenopausal women with and without hormone therapy
  387. A prospective epidemiological study of gastrointestinal health effects due to the consumption of drinking water
  388. Use of Dipyrone during Pregnancy and Risk of Wilmsʼ Tumor
  389. Use of Dipyrone during Pregnancy and Risk of Wilmsʼ Tumor
  390. Conventional Cervical Cytologic Smears vs. ThinPrep Smears
  391. Family history of cancer is a risk factor for squamous cell carcinoma of the head and neck in Brazil: A case‐control study
  392. Transmission of Cervical Human Papillomavirus Infection by Sexual Activity: Differences between Low and High Oncogenic Risk Types
  393. Cancer Causes Revisited: Human Papillomavirus and Cervical Neoplasia
  394. Factors Influencing Regional Lymph Node Metastasis from Laryngeal Carcinoma
  395. Recent advances in the molecular epidemiology of cervical cancer
  396. The effect of cervical loop electrosurgical excision on subsequent pregnancy outcome: North American experience
  397. Parental Exposures to Pesticides and Risk of Wilms' Tumor in Brazil
  398. Associations between Cigarette Smoking and Each of 21 Types of Cancer: A Multi-Site Case-Control Study
  399. Maté, Coffee, and Tea Consumption and Risk of Cancers of the Upper Aerodigestive Tract in Southern Brazil
  400. Molecular Variant Analysis as an Epidemiological Tool to Study Persistence of Cervical Human Papillomavirus Infection
  401. Incidence of Norwalk virus infections during a prospective epidemiological study of drinking water related gastrointestinal illness
  402. A randomized clinical trial of single-dose versus fractionated-dose dactinomycin in the treatment of wilms' tumor. Results after extended follow-up
  403. ARE THE APPARENT EFFECTS OF CIGARETTE SMOKING ON LUNG AND BLADDER CANCERS DUE TO UNCONTROLLED CONFOUNDING BY OCCUPATIONAL EXPOSURES?
  404. Lateness of diagnosis of oral and oropharyngeal carcinoma: Factors related to the tumour, the patient and health professionals
  405. Association between timing of surgery during menstrual cycle and prognosis in pre-menopausal breast cancer
  406. Race and gender influences on the survival of patients with mouth cancer
  407. Multiple cancers of the upper aero-digestive tract: the challenge of risk factor identification
  408. Prognostic factors in laryngeal cancer patients submitted to surgical treatment
  409. Increased survival, limb preservation, and prognostic factors for osteosarcoma
  410. Epidemiological and clinical correlations with genetic characteristics of Wilms' tumor: Results of the Brazilian Wilms' tumor study group
  411. Single-doseversus fractionated-dose dactinomycin in the treatment of wilms' tumor. Preliminary results of a clinical trial
  412. A randomized trial to evaluate the risk of gastrointestinal disease due to consumption of drinking water meeting current microbiological standards.
  413. The Sexually Transmitted Disease Model for Cervical Cancer
  414. Presentation Risk factors for second cancers of the upper respiratory and digestive systems: A case-control study
  415. Response Design options for the study of second cancers
  416. Microcomputer-assisted multivariate survival data analysis using Cox's proportional hazards regression model
  417. Risk factors for oral cancer in Brazil: A case-control study
  418. Epidemiologic Correlates of Cervical Neoplasia and Risk of Human Papillomavirus Infection in Asymptomatic Women in Brazil
  419. Age and lateness of referral as determinants of extra-ocular retinoblastoma
  420. Microcomputer-assisted univariate survival data analysis using Kaplan-Meier life table estimators
  421. Factors of prognostic importance in childhood non-hodgkin's lymphoma treated with two modified lsa2-l2 protocols. A multivariate analysis approach
  422. Plasminogen activator expression and steroid hormone receptors in female breast cancer: A multifactorial study
  423. Correlation patterns of cancer relative frequencies with some socioeconomic and demographic indicators in Brazil: An ecologic study
  424. Catching up with history: Treatment of Wilms' tumor in a developing country
  425. Androgen, estrogen, and progesterone receptor levels in malignant and benign breast tumors: A multivariate analysis approach
  426. Sensitivity, specificity, and predictive value of laparoscopy for the staging of gastric cancer and for the detection of liver metastases
  427. SIMPLE ALGORITHMS FOR THE REPRESENTATION OF DETERMINISTIC AND STOCHASTIC VERSIONS OF THE REEDFROST EPIDEMIC MODEL USING A PROGRAMMABLE CALCULATOR
  428. Immunoserology of malaria
  429. An Oocyst-Transmitted Outbreak of Toxoplasmosis: Patterns of Immunoglobulin G and M over One Year
  430. A monoclonal antibody-based enzyme immunoassay to detect specificities in malarial antisera: a preliminary report
  431. Monoclonal Antibody Characterization of Plasmodium Falciparum Antigens
  432. Computer-assisted multiple categorization of absorbance values in ELISA through pictorial emulation of 96-well plates
  433. Diagnosis of Acute Acquired Toxoplasmosis with the Enzyme-Labelled Antigen Reversed Immunoassay for Immunoglobulin M Antibodies
  434. A Quantitative Method for Determining Toxoplasma gondii, White Cells, and the Volume of Ascitic Fluid in Experimentally Infected Mice
  435. Prospects
  436. Cervix
  437. Introduction
  438. Endometrium
  439. Epidemiology and the Role of Human Papillomaviruses
  440. Screening for Cervical Cancer Using HPV Tests
  441. Assessing Epidemiological Relations and the Role of Measurement Errors
  442. Evidence-Based Policy Recommendations on Screening and Prevention